Compare IOVA & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | CRTO |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.6M | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | IOVA | CRTO |
|---|---|---|
| Price | $2.22 | $19.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $10.36 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 16.6M | 484.8K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.79 |
| EPS | N/A | ★ 3.00 |
| Revenue | $250,425,000.00 | ★ $1,956,800,000.00 |
| Revenue This Year | $60.94 | N/A |
| Revenue Next Year | $60.85 | $1.42 |
| P/E Ratio | ★ N/A | $6.60 |
| Revenue Growth | ★ 175.62 | 0.53 |
| 52 Week Low | $1.64 | $19.00 |
| 52 Week High | $9.30 | $47.27 |
| Indicator | IOVA | CRTO |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 38.96 |
| Support Level | $2.13 | $19.00 |
| Resistance Level | $2.55 | $20.22 |
| Average True Range (ATR) | 0.16 | 0.71 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 25.57 | 19.32 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.